Menu
Search icon
  1. Home Page
    2. ›
  2. Counties
    3. ›
  3. New York
    4. ›
  4. 10001
    5. ›
  5. CORIDEA, LLC

CORIDEA, LLC

Company claim

Is this your business?

Get access!

Company Details

Name: CORIDEA, LLC
Jurisdiction: New York
Legal type: FOREIGN LIMITED LIABILITY COMPANY
Status: Active
Date of registration: 06 Dec 2012 (13 years ago)
Entity Number: 4328722
ZIP code: 10001
County: New York
Place of Formation: Delaware
Address: 134 WEST 26TH STREET, SUITE 1011, NEW YORK, NY, United States, 10001

DOS Process Agent

Name Role Address
THE LLC DOS Process Agent 134 WEST 26TH STREET, SUITE 1011, NEW YORK, NY, United States, 10001

Agent

Name Role Address
HOWARD LEVIN Agent 134 WEST 26TH STREET, SUITE 1011, NEW YORK, NY, 10001

U.S. Small Business Administration Profile

The U.S. Small Business Administration (SBA) helps Americans start, grow, and build resilient businesses.

Note: SBA was created in 1953 as an independent agency of the federal government to aid, counsel, assist and protect the interests of small business concerns; preserve free competitive enterprise; and maintain and strengthen the overall economy of our nation. SBA reviews Congressional and testifies on behalf of small businesses. It assesses the impact of regulatory burden on small businesses.

Website:
www.coridea.com
Phone Number:
201-906-5516
E-mail Address:
hlevin@coridea.com
Contact Person:
HOWARD LEVIN
Ownership and Self-Certifications:
Self-Certified Small Disadvantaged Business
User ID:
P2776493

Unique Entity ID

A UEI is a government-provided number, like a tax ID number, that’s used to identify businesses eligible for federal grants, awards and contracts.

Note: In April 2022, the federal government replaced its old identifier of choice, the Data Universal Numbering System (DUNS) number, with a government-issued UEI. Now all the federal government’s Integrated Award Environment systems use UEI numbers instead of DUNS numbers. So any entity doing business with the federal government must register for a UEI.

CAGE Code:
71NT6
UEI Expiration Date:
2020-08-31

Business Information

URL:
www.coridea.com
Activation Date:
2019-09-01
Initial Registration Date:
2014-01-17

Commercial and government entity program

The The Commercial And Government Entity Code (CAGE) is assigned by the Department of Defense's Defense Logistics Agency (DLA) and represents your company's physical address for GSA's mailings, payments, and administrative records.

Note: A CAGE Code enables a company to contract with the U.S. government, allowing bid on government contracts and to receive government payments. Also for business this means that it's a Verified business entity and Has a validated physical address.

CAGE number:
71NT6
Status:
Active
Type:
Non-Manufacturer
CAGE Update Date:
2025-06-03
CAGE Expiration:
2030-06-03
SAM Expiration:
2026-05-28

Contact Information

POC:
HOWARD LEVIN
Corporate URL:
www.coridea.com

Form 5500 Series

Employer Identification Number (EIN):
320084041
Plan Year:
2022
Number Of Participants:
3
Sponsors Telephone Number:
6077430355
File:
View File
Plan Year:
2021
Number Of Participants:
5
Sponsors Telephone Number:
6077430355
File:
View File
Plan Year:
2020
Number Of Participants:
8
Sponsors Telephone Number:
6077430355
File:
View File
Plan Year:
2018
Number Of Participants:
4
Sponsors Telephone Number:
6077430355
File:
View File

Filings

Filing Number Date Filed Type Effective Date
130313000209 2013-03-13 CERTIFICATE OF PUBLICATION 2013-03-13
121206000153 2012-12-06 APPLICATION OF AUTHORITY 2012-12-06

USAspending Awards / Financial Assistance

Date:
2023-09-01
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
TRANSCUTANEOUS PHRENIC NERVE STIMULATION FOR TREATING OPIOID OVERDOSE - IN THE U.S., AN EXPONENTIAL INCREASE IN OPIOID-RELATED OVERDOSE DEATHS HAS OCCURRED OVER THE LAST DECADE. THE HALLMARK SYMPTOM OF AN OPIOID-RELATED OVERDOSE IS DECREASED RESPIRATION, WHICH CAN RESULT IN PERMANENT HYPOXIC BRAIN INJURY WITHIN MINUTES. THE PURPOSE OF THE PROPOSED RESEARCH IS TO DEVELOP A COMMUNITY-DEPLOYABLE AUTOMATED EXTERNAL RESPIRATION SYSTEM (AERS) DEVICE THAT IS CAPABLE OF MAINTAINING ADEQUATE RESPIRATION IN INDIVIDUALS EXPERIENCING OPIOID-INDUCED RESPIRATORY DEPRESSION - VIA EXTERNAL STIMULATION OF THE PHRENIC NERVE - UNTIL OTHER MEDICAL INTERVENTIONS (E.G., NALOXONE) CAN BE ADMINISTERED OR THE EFFECTS OF THE OPIOIDS DISSIPATE NATURALLY OVER TIME. THE CONCEPT OF THE AERS DEVICE IS MODELED AFTER AUTOMATED EXTERNAL DEFIBRILLATOR DEVICES (AEDS), WHICH ARE NOW WIDELY AVAILABLE IN MEDICAL AND PUBLIC SETTINGS FOR USE BY BOTH MEDICALLY TRAINED AND UNTRAINED INDIVIDUALS. A PROTOTYPE AERS DEVICE WAS DEVELOPED UNDER A PREVIOUS SMALL BUSINESS INNOVATION RESEARCH GRANT AWARDED TO CORIDEA AND DEMONSTRATED TO BE SAFE AND EFFECTIVE IN SUSTAINING BREATHING IN A PRECLINICAL MODEL OF DRUG- INDUCED RESPIRATORY DEPRESSION. THE PROPOSED RESEARCH SEEKS TO QUALIFY THE PROTOTYPE SYSTEM FOR HUMAN USE, DEMONSTRATE FEASIBILITY AND SAFETY IN HUMAN VOLUNTEERS IN A HOSPITAL SETTING, AND THEN DEVELOP A COMMERCIAL SYSTEM CAPABLE OF COMMUNITY DEPLOYMENT. THE CURRENT PROTOTYPE WILL BE FURTHER OPTIMIZED IN MINIATURE PIGS (AIM 1A), AND THEN EVALUATED FOR SAFETY USING RIGOROUS TESTING IN PIGS UNDER FENTANYL-INDUCED RESPIRATORY DEPRESSION WITH DIFFERENT LEVELS OF CHEST WALL COMPLIANCE TO MIMIC FENTANYL-INDUCED “WOODEN CHEST SYNDROME,” AND FINALLY IN THE SETTING OF NALOXONE REVERSAL (AIM 1B). RESULTS FROM AIMS 1A AND 1B WILL BE USED TO SUPPORT AN IDE FOR TESTING THE AERS DEVICE IN A CLINICAL MODEL OF OPIOID-INDUCED RESPIRATORY DEPRESSION IN HEALTHY VOLUNTEERS WITHOUT (AIM 2A) AND WITH OPIOID USE DISORDER (AIM 2B). A COMMERCIAL-GRADE, AED-LIKE DEVICE WILL THEN BE DESIGNED (AIM 3A) AND TESTED IN A HUMAN FACTORS STUDY (AIM 3B). THE DATA COLLECTED IN AIMS 1-3 WILL BE SUBMITTED TO THE FDA FOR APPROVAL OF A PIVOTAL TRIAL (DESIGNED IN COLLABORATION WITH THE FDA), WHICH WILL BE SUPPORTED BY A FUTURE GRANT PROPOSAL. THE AERS DEVICE IS BUILT ON THE SUCCESSFUL CONCEPT FOR TREATING CARDIOVASCULAR DYSFUNCTION AND CAN POTENTIALLY BE USED IN COMBINATION WITH AEDS TO TREAT MULTI- DRUG OVERDOSES (E.G., STIMULANTS + OPIOIDS), AND MAY OFFER A CRITICAL TOOL FOR USE BY MEDICAL AND LAY PERSONS TO REDUCE THE MORBIDITY AND MORTALITY ASSOCIATED WITH OPIOID OVERDOSES.
Obligated Amount:
927319.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2023-08-11
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
MINIMALLY INVASIVE HIGH INTENSITY THERAPEUTIC ULTRASOUND FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY - PROJECT SUMMARY OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) IS A COMMON INHERITED HEART DISEASE THAT CAN CAUSE MAJOR LIMITATIONS TO DAILY ACTS OF LIVING, POOR PROGNOSIS, AND MORTALITY. THERE ARE AS MANY AS 1.5 M PEOPLE WITH HCM IN THE US ALONE, 2/3 OF WHOM HAVE THE OBSTRUCTIVE FORM OF THE DISEASE WITH OVER 50K REMAINING REFRACTORY TO MEDICAL MANAGEMENT AND ARE CANDIDATES FOR SEPTAL REDUCTION THERAPY (SRT). DESPITE THIS, ONLY ~1,200 PATIENTS PER YEAR OF THE 50K CURRENTLY INDICATED RECEIVE SRT, LEAVING THE VAST MAJORITY OF THE MOST SEVERE PATIENTS UNTREATED. THE REASON FOR IS THE HIGHLY INVASIVE NATURE OF EXISTING SRTS THAT CAUSE FREQUENCY CARDIAC RHYTHM ABNORMALITIES REQUIRING IMPLANTATION OF A PACEMAKER OR CARDIOVERTER DEFIBRILLATOR (ICD) AND HAVE UNACCEPTABLY HIGH RATES OF PERI- AND POST- PROCEDURAL MORTALITY (UP TO 10%). ADDITIONALLY, MANY PATIENTS ARE UNSUITABLE FOR EXISTING SRT PROCEDURES DUE TO EXISTING CO-MORBIDITIES AND/OR ANATOMICAL LIMITATIONS. THIS PHASE II SBIR PROPOSES DEVELOPMENT OF A NOVEL TREATMENT FOR OHCM BY PRECISELY TARGETING THE SOURCE OF THE OBSTRUCTION ON THE INTERVENTRICULAR SEPTUM (IVS) USING A NOVEL HIGH-INTENSITY THERAPEUTIC ULTRASOUND (HITU) CATHETER. OUR APPROACH TAKES A RELATIVELY SAFE, FEMORAL VENOUS APPROACH TO THE RIGHT VENTRICLE (RV) USING EXISTING DELIVERY TOOLS AND KNOWHOW WITHIN CARDIAC ELECTROPHYSIOLOGY. TREATMENT FOCUSES ON DELIVERY OF HITU TO SELECTIVELY ABLATE THE ENTIRE MID-MYOCARDIUM OF THE IVS WHILE SPARING THE CARDIAC CONDUCTION SYSTEM ON THE SUB-ENDOCARDIUM (HIS-PURKINJE), THEREBY REDUCING RISK OF HEART BLOCK REQUIRING PACEMAKER OR ICD INSERTION. THIS PROPOSAL BUILDS UPON THE PHASE I-EQUIVALENT WORK IN ACOUSTIC PHYSICS, AND PRE-CLINICAL PROOF OF CONCEPT WITH A PROTOTYPE CATHETER DEMONSTRATING THAT, BY GENERATING DEEP LESIONS IN THE MID-SEPTUM WITH A HITU, THE IVS THICKNESS CAN BE REDUCED BY APPROXIMATELY 30%. BASED ON CATHETER IRRIGATION FEATURES AND HITU’S NATURAL FOCUSING CHARACTERISTICS SPARING THE SUB- ENDOCARDIUM, HEART BLOCK CAN BE AVOIDED EVEN IN THE SETTING OF EXTENSIVE ABLATION IN THIS REGION. THE AIMS OF THIS PROPOSAL WILL FOCUS ON MATURATION OF CATHETER DESIGN ELEMENTS AND MANUFACTURING METHODS TO MAKE THE PROTOTYPE DEVICE SUITABLE FOR CLINICAL EVALUATION, VERIFY THE FUNCTIONALITY AND SAFETY OF THE SYSTEM TO RELEVANT INTERNATIONAL SAFETY STANDARDS (PARTICULARLY IEC 60601-2-62 STANDARDS), AND VALIDATE THE SAFETY, EFFICACY, AND DURABILITY OF THIS THERAPY IN ACUTE AND CHRONIC (3-MONTH) PRECLINICAL MODELS VIA CLINICALLY ACCEPTED MODALITIES (CARDIAC MRI, TTE, CLINICAL PATHOLOGY, GROSS PATHOLOGY AND HISTOPATHOLOGY). THE INFORMATION OBTAINED IN THIS GRANT WILL BE USED IN DIRECT SUPPORT OF EARLY FEASIBILITY IDE SUBMISSION WITH THE FDA AS PART OF A FUTURE PHASE OF THE GRANT. COMMERCIALIZATION OF OUR SYSTEM WILL BRING LIFESAVING THERAPY TO THOUSANDS OF CRITICALLY ILL PATIENTS EVERY YEAR AND EVENTUALLY EXPAND TO TREATMENT OF HCM PATIENTS IN EARLIER STAGES OF THE DISEASE BEFORE LONG- STANDING OBSTRUCTIVE HYPERTROPHY RESULTED IN IRREVERSIBLE HEALTH CONSEQUENCES.
Obligated Amount:
1971939.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-09-22
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
CORIDEA NIH I-CORPS PROGRAM - PROJECT SUMMARY: OPIOID USE DISORDER (OUD) STANDS OUT AS BEING THE MOST LETHAL OF ADDICTIONS. NOT ONLY IS THERE A SIGNIFICANT RISK OF OVERDOSE, THE LIFE SPAN OF A PATIENT WITH OUD DECREASED BY ALMOST 20 YEARS. FURTHERMORE, OUD IS FREQUENTLY COMORBID WITH OTHER DISORDERS, SUCH AS TREATMENT RESISTANT DEPRESSION AND CHRONIC PAIN. THUS, THERE IS A NEED TO IMPROVE TREATMENT OPTIONS FOR OUD AND IT’S COMORBID CONDITIONS. OUR GOAL IS TO DEVELOP A BRAIN STIMULATION APPROACH TO IMPROVE TREATMENT RESPONSE. OUR DEVICE, CALLED ON-DEMAND ELECTROSTIMULATION (ODE) IS DESIGNED TO STIMULATE THE BRAIN REGIONS THAT HAVE BEEN IMPLICATED IN OUD, DEPRESSION, AND CHRONIC PAIN. OUR PHASE I SBIR APPLICATION HAS PROVIDED THE RESOURCES NEEDED TO BEGIN DEVELOPING ODE, INCLUDING BRAIN SIMULATION STUDIES AND BENCH WORK USING HUMAN SKULLS (AS PHANTOMS) TO MEASURE THE ELECTRICAL FIELD GENERATED BY OUR ELECTRODES. THESE STUDIES WILL BE USED TO COMPLETE A VALIDATION AND VERIFICATION PLAN IN PLACE WITH THE FDA. OUR GOAL IN APPLYING TO THE I-CORPS PROGRAM IS TO IMPROVE OUR ABILITY TO AVOID THE COMMON PITFALLS THAT END MOST ACADEMIC/PRIVATE PARTNERSHIPS. THE INSIGHT PROVIDED BY I-CORPS REGARDING MEDICAL REIMBURSEMENT, REGULATORY STRATEGIES, AND PRE-CLINICAL DEVELOPMENT WILL BE USED TO MODIFY AND STRENGTHEN OUR COMMERCIALIZATION PLAN. THROUGH THE I-CORPS PROGRAM, OUR TEAM WOULD BE POSITIONED TO ADOPT A BETTER UNDERSTANDING OF OUR POTENTIAL CUSTOMER NEEDS AND THE ACCEPTABILITY OF IMPLANTED STIMULATION ELECTRODES. THIS WOULD INCLUDE NOT ONLY PATIENT POPULATIONS EXPERIENCING OUD AND COMORBID CONDITIONS, BUT ALSO PHYSICIANS.
Obligated Amount:
278784.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2020-04-10
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
ENDOBRONCHIAL SUPERVALVE FOR THE TREATMENT OF EMPHYSEMA
Obligated Amount:
2166021.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00
Date:
2021-09-24
Link:
View on USAspending
Awarding Agency Name:
Department of Health and Human Services
Transaction Description:
NOVEL MINIMALLY INVASIVE ENDOBRONCHIAL APPROACH FOR LUNG CANCER ABLATION - PROJECT SUMMARY: LUNG CANCER IS ONE OF THE MOST AGGRESSIVE AND COMMON MALIGNANCIES WORLD-WIDE. WHILE SURGICAL RESECTION REMAINS THE BEST CHANCE OF CURE, ONLY 20% OF PATIENTS ARE ELIGIBLE FOR SURGERY. THE REMAINING PATIENTS ARE MANAGED WITH COMBINATIONS OF RADIOTHERAPY AND CHEMOTHERAPY AND MORE RECENTLY WITH LESS INVASIVE STEREOTACTIC RADIOTHERAPY AND PERCUTANEOUS THERMAL ABLATION. PERCUTANEOUS RADIO-FREQUENCY ABLATION (RFA) OR MICROWAVE ABLATION ARE COST-EFFECTIVE TREATMENT OPTIONS FOR UNRESECTABLE TUMORS. THIS MINIMALLY INVASIVE APPROACH, THOUGH EFFECTIVE FOR TREATMENT OF SOME STAGE 1 AND 2 NON-SMALL CELL LUNG CARCINOMAS EITHER ALONE OR IN COMBINATION WITH OTHER THERAPIES, SUFFER IN TERMS OF THEIR ABILITY TO CREATE THERMAL DESTRUCTION OF THE TUMORS WITH SUFFICIENT MARGIN WITHOUT RISKING SERIOUS ADVERSE EVENTS LIKE PNEUMOTHORAX AND COLLATERAL INJURY. THE GOAL OF THIS PROPOSAL IS TO REFINE THE DESIGN OF A FULL-LENGTH, ENDOBRONCHIAL RFA SYSTEM THAT IS COMPATIBLE WITH THE WORKING CHANNEL OF A BRONCHOSCOPE AND CAN ACHIEVE THERMAL ABLATION OF PERIPHERAL NODULES 2-3 CM IN DIAMETER WITH MINIMAL RISK OF PNEUMOTHORAX. OUR INNOVATIVE APPROACH OVERCOMES PAST ATTEMPTS OF USING RFA TO MAKE LARGE LESIONS WITHOUT CROSSING THE AIRWAY BY COMBINING, IN A SINGLE DEVICE, AIR ASPIRATION AND IRRIGATION FLOW TO INCREASE LESION TOGETHER WITH A CUSTOM RF GENERATOR ALGORITHM. OUR DEVICE IS DESIGNED TO BE USED WITH CURRENTLY AVAILABLE TOOLS FOR LUNG TUMOR BIOPSY OR IMAGING (E.G., RADIAL EBUS) AND CAN ALSO BE USED IN CONJUNCTION WITH CONTEMPORARY NAVIGATION AND ROBOTIC SYSTEMS. THIS PROJECT WILL BE COMPLETED IN SEVERAL SEQUENTIAL STAGES. FOR THIS PHASE II SBIR WE WILL OPTIMIZE AND REFINE OUR INNOVATIVE APPROACH TO RFA, DEVELOP A CLINICAL-GRADE SYSTEM WITH VERIFICATION AND VALIDATION TESTS, AND DEMONSTRATE SAFETY AND CONTROLLABILITY IN PRECLINICAL STUDIES. THE INFORMATION OBTAINED IN THIS GRANT WILL BE USED DIRECTLY TO GUIDE EFS-IDE SUBMISSION WITH THE FDA AS PART OF A FUTURE PHASE OF THE GRANT.
Obligated Amount:
1567912.00
Face Value Of Loan:
0.00
Total Face Value Of Loan:
0.00

Trademarks Section

Serial Number:
85417600
Mark:
CORIDEA
Status:
REGISTERED AND RENEWED
Mark Type:
SERVICE MARK
Application Filing Date:
2011-09-08
Mark Drawing Type:
Standard character mark
Mark Literal Elements:
CORIDEA
USPTO Link:
View Trademark Status and Document Retrieval (TSDR)

Goods And Services

For:
Consulting services in the field of medical care; Consulting services in the field of offshore medical services
First Use:
2012-09-01
International Classes:
044 - Primary Class
Class Status:
Active
For:
Basic and clinical research in the field of respiratory science and medicine; Consulting services in the field of medical physics; Medical and scientific research, namely, conducting clinical trials; Providing medical and scientific research information in the field of clinical trials; Providing med...
First Use:
2012-09-01
International Classes:
042 - Primary Class
Class Status:
Active

Paycheck Protection Program

Date Approved:
2020-05-01
Loan Status:
Paid in Full
SBA Guaranty Percentage:
100
Initial Approval Amount:
160007
Current Approval Amount:
160007
Race:
Unanswered
Ethnicity:
Unknown/NotStated
Gender:
Unanswered
Veteran:
Unanswered
Forgiveness Amount:
161583.78

Reviews Leave a review

This company hasn't received any reviews.

Related by officers

THE LLC

HITTERZZ, LLC PLJ PROPERTIES, LLC 7119 20TH AVE. LLC THE TALLY-HO INN, LLC NEXIS REALTY GROUP, LLC KILBORN LLC BKN PROPERTIES, LLC COTTON TEES, LLC PLAYDATE 4 YOU LLC CONTEMPORARY FILM FUND LLC

HOWARD LEVIN

AXON THERAPIES, INC. CIBIEM, INC.

Related by address

134 WEST 26TH STREET, SUITE 1011, NEW YORK, NY, United States, 10001

CIBIEM, INC.

Date of last update: 26 Mar 2025

Sources: New York Secretary of State

Privacy policy Policy
About us About us
Contacts Contact us

© 2025 bizyork.com, Part of Big Data Integrated